Immatics N.V. (IMTX) Stock
IMTX has an Alpha Score of 11 out of 100 (poor), computed on Nov 4, 2026 from 2 of 4 sub-scores. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is IMTX's Alpha Score?
How it works →Alpha Score of 11 reflects poor overall profile with poor momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Are Immatics N.V. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 26, 26 | Perceptive Advisors Llc | Director | BUY | 863.1K | $7.5M |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are IMTX's key statistics?
Key statistics as of Nov 11, 2026
How does IMTX's valuation compare with the Healthcare sector?
| Metric | IMTX | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -495.27% | 3.60% | 175 |
| Return on equity | -47.04% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
IMTX price chart
Powered by TradingViewWhat does Immatics N.V. do?
Immatics N.V. is a biotechnology company dedicated to the discovery and development of T-cell redirecting cancer immunotherapies. The company's primary function is to harness the power of the body's immune system to target and eliminate cancer cells, facilitating the development of personalized treatment approaches. Immatics is actively engaged in advancing its unique focus on cancer-specific targets and proprietary platforms, including Xpresident and ACTengine, which have been designed to identify and exploit tumor-specific targets. This company's work significantly impacts the biotechnology sector, particularly within oncology, where innovative therapies are continuously needed to address various cancer types. Immatics strives to bridge cutting-edge science with clinical application, playing a vital role in the medical R&D ecosystem. Headquartered in Tuebingen, Germany, with additional operations in Houston, Texas, Immatics represents a notable player in the intersection of biotechnology and immunotherapy, contributing pivotal advancements to the treatment of cancer and underscoring the momentum of precision medicine in the modern healthcare landscape.